853
Views
2
CrossRef citations to date
0
Altmetric
Bedside to Bench Report

Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?

ORCID Icon ORCID Icon, , , &
Pages 659-663 | Received 10 Nov 2017, Accepted 03 Mar 2018, Published online: 13 Apr 2018

Figures & data

Figure 1. IHC analysis of CDX2 expression performed on formalin-fixed, paraffin-embedded tissue sections of the resected liver metastasis, which revealed a mutation in KRAS gene. IHC: immunohistochemical.

Figure 1. IHC analysis of CDX2 expression performed on formalin-fixed, paraffin-embedded tissue sections of the resected liver metastasis, which revealed a mutation in KRAS gene. IHC: immunohistochemical.

Figure 2. Radiological assessment before (A) and after (B) 4 cycles of chemotherapy with FOLFOX and panitumumab. A: Basal CT scan, October 23, 2015. B: CT scan, December 17, 2015.

Figure 2. Radiological assessment before (A) and after (B) 4 cycles of chemotherapy with FOLFOX and panitumumab. A: Basal CT scan, October 23, 2015. B: CT scan, December 17, 2015.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.